Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment

Annals of the Rheumatic Diseases · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles